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SUMMARy
Present concepts of the interrelationship between oestro-
gens, endogenous and exogenous, and the development of
atheromatosis and coronalY heart disease in the human
female are reviewed. Aspects of research conducted by me
at Groote Schuur Hospital, Cape Town, are incorporated
in the discussion. The current role of oestrogen replace-
ment therapy in the prevention of coronary heart disease
in postmenopausal females is presented. It is concluded
that although this role at present is limited, there is hope
for the development of new oestrogenic steroids with a
more specific effect on cholesterol metabolism. Finally,
a plea is made for conservatism with ovaries during gynae-
cological operations on young females.
Some investigators have noted that the premenopausal
female, compared with the human male, is protected
against coronary accidents.'" The sex difference is alleged
to be due to oestrogens.
The purpose of this paper is to review present concepts
of the inter-relationship between oestrogens, endogenous
and exogenous, and the development of atheromatosis and
coronary heart disease. Aspects of research conducted at a
Menopause Clinic, Groote Schuur Hospital, will be in-
corporated in the discussion.' Finally, some conclusions as
to the current role of oestrogen therapy in the prevention
of coronary heart disease in postmenopausal females will
be presented.
Normal Cholesterol Balance
The circulating cholesterol is largely synthesized in the
liver and discharged into plasma bound to lipoproteins.
The plasma cholesterol pool reflects the net result of a
series of reactions which are donating sterol to the pool
while others are removing steroL"
Among western populations and the prosperous moiety
of non-White populations serum cholesterol and other
blood lipids rise with age.'" Serum cholesterol is thought to
increase from about 180 mg/lOO ml between the ages of
20 and 30 years to about 220'·'13 between the ages of 50 and
60 years.' The levels vary, however, in different population
groups. For example, Barr' recorded mean levels of 197
in normal women aged 18 - 35 and 252 in normal women
aged 45 - 65 years. Oliver and Boyd" reported mean levels
of 217 for women aged 40 - 49 years, 240 for those aged
50 - 54 years and 259 for those aged 55 - 59 years. The
risks of coronary thrombosis are said to be seriously in-
creased if serum cholesterol levels exceed 250-",,'
Cholesterol is a precursor of oestrogenic hormones."'"
Endogenous oestrogens appear to influence cholesterol
metabolism in at least two ways. There is an effect on the
biosynthetic mechanism and also an influence on the rate
of degradation or excretion.' Thus these oestrogens appear
to exert an effect on human plasma cholesterol and lipid -
Iipoprotein levels.'·3,11,18
·Date received: 15 December 1970.
Coronary Risk Factors
Atheromatosis is a metabolic disease that is influenced
by many factors.' -%3 The development of atheromatous
lesions does not lend itself to precise measurement in
the living. However, the extent and severity of coronary
atheromatosis determines the risk of ischaemic heart
disease in a given population." This presentation is con-
cerned with only one phase of atheromatosis, namely, its
relation to ovarian function and plasma cholesterol.
Coronary risk factors are those abnormalities demon-
strable in persons free of coronary heart disease (CHD)
and known to be associated with significantly increased
risk of developing the disease in subsequent years.
Numerous prospective studies on western populations have
indicated a close correlation between the moiety with
elevated cholesterol levels and their proness to ischaemic
heart disease.H,tS,,,.,. Population groups with hyper-
cholesterolaemia experience four times as many heart
attacks as those with low serum cholesterol levels." This
strong relationship is well shown in the Framingham
study"''"'" and in the Los Angeles heart study.'" Katz and
Stamler" have demonstrated experimentally a similar re-
lationship. They noted that feeding cholesterol to cockerels
produced coronary atherosclerosis.
In western populations a similarity exists in the pro-
portions of the leading causes of death." Thus CHD
accounts for about one-third, cancer one-quarter or less
and 'strokes' 10% - 15% of total mortality. An important
question, therefore, in improving mortality statistics is
whether long-term reduction of hypercholesterolaemia will
in turn reduce the incidence of atheromatosis and subse-
quent ischaemic heart disease. In this direction it is im-
portant to determine factors responsible for increasing and
for decreasing plasma cholesterol levels."
Oophorectomy and Coronary Heart Disease
Considerable evidence, experimental and clinical, is
available indicating that endogenous ovarian oestrogen
secretion plays a key role in protecting women against
clinical atheromatous (atherosclerotic), coronary heart
disease. This evidence is well reviewed by Berkson et al."
and key references only will be discussed below.
Numerous studies have been done on the effects of
castration or premature menopause on the occurrence of
both clinical heart disease and autopsy evidence of
atherosclerosis in women.",33." Wuest et al" compared the
degree of sclerosis in hearts of bilaterally oophorectomized
women with hearts of men and women of comparable
ages. They found that the degree of coronary sclerosis in
oophorectomized women was greater than in control
women but less than in control men. Oliver and Boyd"
reported that bilateral oophorectomy was followed by the
premature development of clinical coronary artery disease;
similar findings were found by Robinson et al." Higano
and Cohen" reported the risk to be 4-fold. Novak and
WilIiams" stated that the data of Robinson et al.'" and
Oliver and Boyd," being clinical in nature, could not be as
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Thus, in the human, the administration of oestrogenic
substances at certain dosages produces a depression in the
plasma cholesterol concentration and the dosage necessary
to produce this effect on the plasma cholesterol level is in
excess of the threshold oestrogenic dose." However, there
are insufficient data at this stage to allow more than
speculation on the possible mode of action of the oestrogens
in cholesterol metabolism.
Experimentally, Pick et al." have shown that administra-
tion of oestrogens inhibits coronary atherogenesis in
cockerels fed a cholesterol-supplemented diet. There are no
comparable studies in man. Oliver and Boyd43 administered
oestrogen to survivors of myocardial infarction. They found
that, although significant reduction of the serum cholesterol
was evident throughout the 5 years of treatment, the
continued reduction of serum lipids did not improve prog-
nosis once myocardial infarction had occurred. Similar
findings were reported by Marmorston et al.' Other studies
have shown the effects of oestrogens on serum lipid pat-
terns in postmenopausal women,"'" In most cases 1·25 mg
of mixed conjugated equine oestrogens daily was adequate
to produce a fall in serum cholesterol.
Numerous workers have attempted to prove that exo-
genous oestrogen therapy decreases the incidence of
coronary heart diseases, but there is no conclusive proof
to date.',3,43,.. Despite the above lack of definite evidence
there is a growing tendency towards the empirical use of
long-term exogenous oestrogen therapy in the postmeno-
pausal woman to prevent ischaemic heart disease,'T."
GROOlE SCHUUR SERIES
The discussion presented thus far illustrates that there are
still many aspects of this complex inter-relationship re-
quiring further elucidation or confirmation. The Oroote
Schuur study' was planned to evaluate just two of these
aspects, namely the effect of oophorectomy on plasma
cholesterol levels and whether exogenous oestrogen admini-
stration to identical and statistically comparable groups
of patients could cause a lowering of these values. It is
not the purpose of this paper to present the detailed results,
which are reported elsewhere,' but to summarize the more
important and pertinent findings.
Several selected groups of females were investigated
through a Menopause Research Clinic established for the
purpose, at Oroote Schuur Hospital, Cape Town. These
groups included normal premenopausal females and
patients who had undergone hysterectomy with and with-
out bilateral oophorectomy. A group of 50 oophorecto-
mized female volunteers were further observed for a
period of 1 year, during which time control observations
preceded single-blind cross-over administration of two
forms of oestrogen and a placebo.
In brief, there was considerable overlap in values be-
tween the various groups investigated. Oophorectomy was
not shown in the short term (less than 2 years) to increase
significantly the serum cholesterol value. However, oestra-
diol valerate (Progynova, Schering) administration to
oophorectomized females was of some benefit in reducing
the value of serum cholesterol (p<0·05). In this respect
mixed conjugated equine oestrogens (premarin, Ayerst)
were non-effective.
GENERAL DISCUSSION AND CONCLUSIONS
The results of the Oroote Schuur Study do not agree with
the findings of Oliver and Boyd'" who reported oophorec-
tomy to produce an increase in the plasma cholesterol con-
centration of about 15 % to 30% of the pre-operative value;
nor with Sznajderman and Oliver39 who showed spon-
taneous premature menopause to result in elevation of





















objective and precise as data obtained at autopsy. Regard-
less of initial age at operation or years intervening before
death, they could find no significant differences in the
incidence of atherosclerosis in statistically comparable
groups of castrated and control patients at autopsy. A
follow-up study'T suggested that operation before the age
of 40 years might be of significance. Parrish et al." sus-
pected that an important factor overlooked by previous
writers was the time interval between castration and the
'eiltpected date' of the normal menopause. From a study
of autopsy records they found that castrated patients did
have an excess of coronary atherosclerosis and myocardial
infarcts, but this was directly related to the time interval
from castration to 'expected menopause' and the time
interval from castration to death. No excessive coronary
atherosclerosis was found in women castrated after the age
of 41 years in contrast to those castrated when younger;
.excessive coronary atherosclerosis became apparent about
14 years after castration. They concluded that women
castrated before the age of 40 who were expected to sur-
vive more than 14 years were at high risk of developing
coronary heart disease. Finally, in a 6 - 20-year follow-up
study of 35 women who had undergone spontaneous pre-
mature menopause, Sznajderman and Oliver39 further sup-
ported the view that cessation of ovarian activity, whether
premature or at the time of a normal menopause, leads
to an increalie in the incidence of ischaemic heart disease
and in serum lipid levels in later life.
Thus the evidence as to the protective effect of the
functioning ovary is convincing. Unfortunately, as yet the
supporting evidence for the next logical step in this argu-
ment is not as sound, namely the effect of replacement
exogenous oestrogen on the female cardiovascular system.
Exogenous Oestrogens and Coronary Heart Disease
A wide range of oestrogenic substances has been studied
for their effects on cholesterol metabolism in experimental
animals and to a lesser extent in humans."'" Oestradiol,
oestradiol benzoate and diethylstilboestrol are more potent
than oestrone as regards both lipid effects and oestrogenic
activity. Ethinyl oestradiol has less effects on lipids and is
more potent as an oestrogen than oestrone."'" Table I
gives a summary from Boyd" of a few of the oestrogens
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TABLE /1. SERUM CHOLESTEROL LEVELS
Despite the limitations of direct comparison, the sum-
mary in Table II is of interest. Thus the oophorectomized
groups of Oliver and Boyd'" and the Groote Schuur Study'
and the normal women of Barr's study' and the Groote
Schuur group' demonstrate remarkably similar results. It
is therefore concluded that bilateral oophorectomy in the
premenopausal female does not result in an increase in the
serum cholesterol for at least 2 years. This lack of early
direct response to endogenous oestrogen withdrawal would
therefore suggest oestrogens to be of no more than secon-
dary importance in the known relationship of increasing
blood cholesterol with ageY Speculation as to what the
primary factor or factors that are responsible for differences
in cholesterol with age and between the sexes may be is
beyond the scope of the present article.
The potential ability of exogenous oestrogen therapy to
reduce serum cholesterol values appears well docu-
mented."'· ...·... In the Groote Schuur study,' administration
of oestradiol valerate (Progynova) continuously for 6
months to 50 oophorectomized females resulted in a de-
crease of the total serum cholesterol value of possible
significance only (p<0·05). Moreover, mixed conjugated
equine oestrogen (Premarin) administration had little or no
effect on the cholesterol values. Robinson et al.'" reported
a significant serum cholesterol lowering effect at I month,
3 months, 6 months and 12 months when administering
conjugated oestrogens to oophorectomized females. There
is no obvious explanation for the failure of the Groote
Schuur study to confirm these findings. It certainly would
appear that different exogenous oestrogens have different
effects and the hope for the future is the synthesis of an
oestro§en with a more potent effect on serum cholesterol
levels.
None the less, the negative findings of the Groote Schuur
investigation in relation to the effect of oophorectomy on
serum cholesterol and the minimal short-term value of
subsequent exogenous oestrogen therapy to oophorecto-
mized females are considered sufficient evidence for
questioning the empirical use of such hormones for the
prevention of ischaemic heart disease in postmenopausal
women...·"'··,
The conclusion is that despite the relatively small de-
pressive effect of pt"esently available exogenous oestrogens
on blood cholesterol values, the role of such therapy in the
prevention of coronary heart disease is no more than a
minor one. Finally it is emphasized that the effects of
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the same. The convincing direct evidence of the protective
role of endogenous oestrogens in the development of
coronary atheromatosis is a sound argument against the
pernicious operation of bilateral oophorectomy in young
females. A plea is therefore made for conservatism with
ovaries during gynaecological operations on young
females." The hope for the future is the isolation and
synthesis of all the natural endogenous ovarian oestrogens
and their ultimate availability for true oestrogen replace-
ment therapy in the postmenopausal female.
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